ライフサイエンスコーパス: beta-2 adrenergic receptor

1 ugh it attenuated the resensitization of the beta 2-adrenergic receptor.

2 uced metastasis through up-regulation of the beta-2 adrenergic receptor.

3 eine residue (C607) after stimulation of the beta(2) adrenergic receptor.

4 nges in the G protein-coupling domain of the beta(2) adrenergic receptor.

5 ion and trafficking of the G protein-coupled beta(2)-adrenergic receptor.

6 the internalization of the Galpha(s)-coupled beta(2)-adrenergic receptor.

7 geneity of the liganded states formed by the beta(2)-adrenergic receptor.

8 hosphatases, associating reversibly with the beta(2)-adrenergic receptor.

9 l as insulin-stimulated sequestration of the beta(2)-adrenergic receptor.

10 pid phosphorylation and sequestration of the beta(2)-adrenergic receptor.

11 plicating Akt in downstream signaling to the beta(2)-adrenergic receptor.

12 MP generation elicited by stimulation of the beta(2)-adrenergic receptor.

13 ts ability to promote internalization of the beta(2)-adrenergic receptor.

14 udes insulin-stimulated sequestration of the beta(2)-adrenergic receptor.

15 l as insulin-stimulated sequestration of the beta(2)-adrenergic receptor.

16 tes clathrin-mediated internalization of the beta(2)-adrenergic receptor.

17 nt mutants to inhibit internalization of the beta(2)-adrenergic receptor.

18 of TM3 and TM6 in the inactive state of the beta(2)-adrenergic receptor.

19 nal reported after agonist occupation of the beta(2)-adrenergic receptor.

20 of Glu-268(6.30) and of Asp-130(3.49) in the beta(2)-adrenergic receptor.

21 tly blocks the ability of gravin to bind the beta(2)-adrenergic receptor.

22 in, as well as enhanced sequestration of the beta(2)-adrenergic receptor.

23 he known interaction involving Ser204 of the beta(2)-adrenergic receptor.

24 first study of CB2 based on the structure of beta(2)-adrenergic receptor.

25 late two different GPCRS: rhodopsin, and the beta(2)-adrenergic receptor.

26 containing transferrin and agonist-activated beta(2)-adrenergic receptor.

27 ant D2 dopamine receptor and the beta(1) and beta(2) adrenergic receptors.

28 cells to apoptosis through interaction with beta(2)-adrenergic receptors.

29 bligate for resensitization and recycling of beta(2)-adrenergic receptors.

30 protein kinase B) in the internalization of beta(2)-adrenergic receptors.

31 dilated cardiomyopathy model overexpressing beta(2)-adrenergic receptors.

32 analyze agonist-dependent internalization of beta(2)-adrenergic receptors.

33 s desensitization and down-regulation of the beta(2)-adrenergic receptors.

34 s intact in JT1 cells and internalization of beta(2)-adrenergic receptor, a GPCR that internalizes an

35 e we propose an activation mechanism for the beta(2)-adrenergic receptor, a prototypical GPCR, based

36 ng requires the integrity of Tyr(350) of the beta(2)-adrenergic receptor, a residue phosphorylated in

37 central structural feature in the ECS of the beta(2) adrenergic receptor: a salt bridge linking extra

38 We propose that the beta(2)-adrenergic receptor activates Src via two indepe

39 at Thr-382 and becomes dephosphorylated upon beta(2)-adrenergic receptor activation in COS-1 cells.

40 es revealed abnormal cAMP accumulation after beta(2)-adrenergic receptor activation in PI3Kgamma(-/-)

41 the beta(2)-adrenergic receptor, even though beta(2)-adrenergic receptor activation promoted tyrosyl

42 tosidase (adeno-beta-gal, n=11) or the human beta(2)-adrenergic receptor (adeno-beta(2)-AR, n=15) wer

43 Beta-2 adrenergic receptor (ADRB2) is the primary target

44 IC1 is a direct transcriptional repressor of beta-2 adrenergic receptor (ADRB2).

45 (beta2AR) in wound scarring, the ability of beta 2 adrenergic receptor agonist (beta2ARag) to alter

46 BDs) and reperfused with the addition of the beta(2)-adrenergic receptor agonist isoproterenol (iso),

47 chimeric TGF-beta type II receptor restored beta(2)-adrenergic receptor agonist-stimulated alveolar

48 ical mediator of acute lung injury, inhibits beta(2)-adrenergic receptor agonist-stimulated vectorial

49 cute asthma exacerbation is the short-acting beta(2)-adrenergic receptor agonist; however, there is v

50 Salmeterol (10 muM), a beta-2-adrenergic receptor agonist, significantly increa

51 lthough short-acting and long-acting inhaled beta(2)-adrenergic receptor agonists (SABA and LABA, res

52 ts supported encystation, whereas alpha- and beta(2)-adrenergic receptor agonists did not.

53 Exogenous or endogenous beta(2)-adrenergic receptor agonists enhance alveolar ep

54 Insulin stimulates Src to associate with the beta(2)-adrenergic receptor/AKAP250/protein kinase A/pro

55 Here we show that a mutant beta(2) adrenergic receptor and a mutant mu opioid recep

56 Recently, the structures of the beta(1) and beta(2) adrenergic receptors and the adenosine A(2a) rec

57 ergic receptor stimulation, markedly reduced beta(2)-adrenergic receptor and angiotensin II receptor

58 upon stimulation, whereas GPCRs such as the beta(2)-adrenergic receptor and CXCR4 are not capable of

59 The beta(2)-adrenergic receptor and delta opioid receptor re

60 lubilized a fusion protein consisting of the beta(2)-adrenergic receptor and green fluorescent protei

61 sine kinase Src regulates resensitization of beta(2)-adrenergic receptors and docks to gravin.

62 2 blocks the ability of insulin to sequester beta(2)-adrenergic receptors and the translocation of th

63 nents of this pathway, particularly PKA, the beta 2-adrenergic receptor, and BCAM/Lu, should be furth

64 ion of GRK5 by the PDGFRbeta, but not by the beta(2)-adrenergic receptor, and that by activating GRK5

65 gnaling of the ghrelin receptor, GPR119, the beta(2)-adrenergic receptor, and the neurokinin-1 recept

66 fused a cocktail of alpha(1)-, beta(1)-, and beta(2)-adrenergic receptor antagonists into the mPFC pr

67 ide blocked high affinity agonist binding to beta(2) adrenergic receptors (AR) and inhibited beta(2)A

68 Beta(1) and beta(2) adrenergic receptors (AR) regulate the intrinsic

69 current (I(Ca,L)) stimulated by beta(1)- or beta(2)-adrenergic receptor (AR) agonists in cat atrial

70 Cardiac-specific overexpression of the human beta(2)-adrenergic receptor (AR) in transgenic mice (TG4

71 Transgenic cardiac beta(2)-adrenergic receptor (AR) overexpression has resu

72 Differential modes for beta(1)- and beta(2)-adrenergic receptor (AR) regulation of adenylyl

73 cromolecular signaling complex necessary for beta(2)-adrenergic receptor (AR) regulation of I(Ca,L).

74 Although ligand-free, constitutive beta(2)-adrenergic receptor (AR) signaling has been demo

75 es adenylate cyclase (AC)/cAMP and increases beta(2)-adrenergic receptor (AR) stimulation of L-type C

76 We tested the hypothesis that beta(1)- and beta(2)-adrenergic receptor (AR) subtypes differentially

77 ve revealed that one of these receptors, the beta(2)-adrenergic receptor (AR), also couples to the in

78 We recently reported that beta(1)- and beta(2)-adrenergic receptors (AR) regulate the intrinsic

79 the cell surface targeting of alpha(2B)- and beta(2)-adrenergic receptors (AR).

80 Both beta(1) and beta(2) adrenergic receptors are expressed in human and

81 on, many G protein-coupled receptors such as beta(2)-adrenergic receptors are internalized via beta-a

82 Crystal structures of engineered human beta 2-adrenergic receptors (ARs) in complex with an inv

83 Stimulation of beta(1)- and beta(2)-adrenergic receptors (ARs) in the heart results

84 ratinocytes (HOK) express the alpha(2B)- and beta(2)-adrenergic receptors (ARs).

85 rescence microscopy to visualize the FPR and beta(2)-adrenergic receptor as they internalized in the

86 The beta(2)-adrenergic receptor (B2AR) and delta-opioid rece

87 The prototypical beta-2 adrenergic receptor (B2AR) activates Galpha stimu

88 The beta-2 adrenergic receptor (B2AR) is well known to form

89 nvestigated this question by focusing on the beta-2 adrenergic receptor (B2AR), a G protein-coupled r

90 requirements to switch the recycling of the beta-2 adrenergic receptor (B2AR), a prototypic signalin

91 ined crystal structures of rhodopsin and the beta 2-adrenergic receptor (beta 2-AR) offer insight int

92 ng and predicting activation pathways of the beta 2-adrenergic receptor (beta 2-AR), folding of the F

93 C-terminal lysines to arginines in the human beta 2-adrenergic receptor (beta 2AR) (K348/372/375R).

94 Classically, the beta 2-adrenergic receptor (beta 2AR) and other members

95 transmitter norepinephrine (NE) binds to the beta 2-adrenergic receptor (beta 2AR) expressed on vario

96 The beta(2) adrenergic receptor (beta(2)AR) activation of Gs

97 undertaken to extend emerging evidence that beta(2) adrenergic receptor (beta(2)AR) agonists, in add

98 We have recently shown that Abeta binds to beta(2) adrenergic receptor (beta(2)AR) and activates pr

99 yl-terminal sequences NDSLL and EDSFL of the beta(2) adrenergic receptor (beta(2)AR) and platelet-der

100 Using the inactive structure of the human beta(2) adrenergic receptor (beta(2)AR) as a guide, we d

101 basal activation of the G protein Gs by the beta(2) adrenergic receptor (beta(2)AR) by using purifie

102 ansmembrane conductance regulator (CFTR) and beta(2) adrenergic receptor (beta(2)AR) can bind ezrinra

103 Agonist-induced ubiquitination of the beta(2) adrenergic receptor (beta(2)AR) functions as an

104 Recent experimental studies on the beta(2) adrenergic receptor (beta(2)AR) indicate that st

105 The beta(2) adrenergic receptor (beta(2)AR) is a prototypica

106 harmaceutical targets, and of the GPCRs, the beta(2) adrenergic receptor (beta(2)AR) is one of the mo

107 id antibody fragment (nanobody) to the human beta(2) adrenergic receptor (beta(2)AR) that exhibits G

108 oplasmic end of transmembrane 6 (TM6) of the beta(2) adrenergic receptor (beta(2)AR), adjacent to the

109 DTRL present at the carboxyl termini of the beta(2) adrenergic receptor (beta(2)AR), the platelet-de

110 ceptor-mediated G protein activation for the beta(2) adrenergic receptor (beta(2)AR).

111 mation of a complex with agonist-bound human beta(2) adrenergic receptor (beta(2)AR).

112 y of AMPA receptors by a mechanism involving beta(2) adrenergic receptor (beta(2)AR).

113 y of constitutive GRK phosphorylation of the beta(2)-adrenergic receptor (beta 2AR), in vitro GRK pho

114 ort desensitization and sequestration of the beta(2)-adrenergic receptor (beta(2)-AR) and the angiote

115 Phosphorylation of the beta(2)-adrenergic receptor (beta(2)-AR) by protein kina

116 Polymorphisms of the beta(2)-adrenergic receptor (beta(2)-AR) can affect regu

117 reviously reported that association with the beta(2)-adrenergic receptor (beta(2)-AR) facilitates fun

118 -dependent pathway and degraded, whereas the beta(2)-adrenergic receptor (beta(2)-AR) failed to inter

119 anes from a HEK-293 cell line expressing the beta(2)-adrenergic receptor (beta(2)-AR) have been immob

120 Cellular expression of the beta(2)-adrenergic receptor (beta(2)-AR) is suppressed a

121 studies have indicated that some aspects of beta(2)-adrenergic receptor (beta(2)-AR) signaling are i

122 To determine whether beta(2)-adrenergic receptor (beta(2)-AR) stimulation con

123 the role of group-conserved residues in the beta(2)-adrenergic receptor (beta(2)-AR), amino acid rep

124 of rhodopsin were replaced with those of the beta(2)-adrenergic receptor (beta(2)-AR).

125 beta(2)-Adrenergic receptor (beta(2)AR) agonists are the

126 or by treatment with bronchodilators such as beta(2)-adrenergic receptor (beta(2)AR) agonists, indica

127 opic therapeutic expression, we utilized the beta(2)-adrenergic receptor (beta(2)AR) as a scaffold to

128 was constructed using the x-ray structure of beta(2)-adrenergic receptor (beta(2)AR) as the template.

129 denoviral-mediated overexpression of a human beta(2)-adrenergic receptor (beta(2)AR) cDNA increases b

130 have suggested that two polymorphisms of the beta(2)-adrenergic receptor (beta(2)AR) gene at codons 1

131 Although downregulation of the prototypical beta(2)-adrenergic receptor (beta(2)AR) has been extensi

132 s study, we investigated the significance of beta(2)-adrenergic receptor (beta(2)AR) in age-related i

133 19 nuclear magnetic resonance) labels in the beta(2)-adrenergic receptor (beta(2)AR) in complexes wit

134 Stimulation of the beta(2)-adrenergic receptor (beta(2)AR) in human embryon

135 messenger dynamics stimulated by endogenous beta(2)-adrenergic receptor (beta(2)AR) in living cells.

136 escale molecular dynamics simulations of the beta(2)-adrenergic receptor (beta(2)AR) in multiple wild

137 of structural segments stabilizing the human beta(2)-adrenergic receptor (beta(2)AR) in the absence a

138 ubiquitin ligase Mdm2 is critical for rapid beta(2)-adrenergic receptor (beta(2)AR) internalization.

139 Genetic variants at the beta(2)-adrenergic receptor (beta(2)AR) may modify asthm

140 -type and mutant GRK2s were expressed with a beta(2)-adrenergic receptor (beta(2)AR) mutant that is r

141 Stimulation of CD86 and the beta(2)-adrenergic receptor (beta(2)AR) on a B cell, eit

142 Stimulation of the beta(2)-adrenergic receptor (beta(2)AR) on a CD40L/inter

143 orphic variant (beta(1)AR-Arg(389)), and the beta(2)-adrenergic receptor (beta(2)AR) or a loss-of-fun

144 displayed equivalent binding to recombinant beta(2)-adrenergic receptor (beta(2)AR) reconstituted in

145 ne the final composition of solutions of the beta(2)-adrenergic receptor (beta(2)AR) reconstituted wi

146 beta(2)-Adrenergic receptor (beta(2)AR) stimulation of C

147 coupled receptors and was validated with the beta(2)-adrenergic receptor (beta(2)AR) system.

148 For the beta(2)-adrenergic receptor (beta(2)AR) this requires ub

149 Agonist-stimulated beta(2)-adrenergic receptor (beta(2)AR) ubiquitination i

150 al dynamics of the transmembrane core of the beta(2)-adrenergic receptor (beta(2)AR), a prototypical

151 beta(1)-adrenergic receptor (beta(1)AR), the beta(2)-adrenergic receptor (beta(2)AR), and the gamma-a

152 BCR) and/or a neurotransmitter receptor, the beta(2)-adrenergic receptor (beta(2)AR), may cooperate t

153 Here we use the beta(2)-adrenergic receptor (beta(2)AR), the archetypal

154 mster fibroblasts transfected to express the beta(2)-adrenergic receptor (beta(2)AR), the beta(2)AR a

155 Here, we show that the beta(2)-adrenergic receptor (beta(2)AR), the trimeric G(

156 ability of isoproterenol, an agonist of the beta(2)-adrenergic receptor (beta(2)AR), to stimulate ex

157 m other G-protein-coupled receptors, such as beta(2)-adrenergic receptor (beta(2)AR), which internali

158 itutions at Glu122(3.41) in the well-studied beta(2)-adrenergic receptor (beta(2)AR), which was predi

159 HASM significantly attenuated isoproterenol (beta(2)-adrenergic receptor (beta(2)AR)-mediated)- and 5

160 semble of conformers of a prototypical GPCR, beta(2)-adrenergic receptor (beta(2)AR).

161 tiating clathrin-mediated endocytosis of the beta(2)-adrenergic receptor (beta(2)AR).

162 ts as a positive allosteric modulator of the beta(2)-adrenergic receptor (beta(2)AR).

163 -like modifier 1 (SUMO-1) upon activation of beta(2)-adrenergic receptor (beta(2)AR).

164 uence of two common polymorphic forms of the beta(2)-adrenergic receptor (beta(2)AR): the Gly16 and G

165 stribution, dynamics, and trafficking of the beta(2)-adrenergic receptor (beta(2)AR; a type A recepto

166 ry G protein Galpha(s), such as beta(1)- and beta(2)-adrenergic receptors (beta(1)ARs and beta(2)ARs)

167 beta(2)-adrenergic receptors (beta(2)-AR) are low abunda

168 beta(2)-Adrenergic receptors (beta(2)-ARs) are low abund

169 ow that at low concentrations of an agonist, beta(2)-adrenergic receptors (beta(2)-ARs) signal throug

170 lae, including redistribution of sarcolemmal beta(2)-adrenergic receptors (beta(2)AR) and localized s

171 Although beta(2)-adrenergic receptors (beta(2)AR) are expressed o

172 beta(2)-adrenergic receptors (beta(2)AR) of all species

173 c (M2R), D1 (D1R) and D2 (D2R) dopamine, and beta(2)-adrenergic receptors (beta(2)AR) was assessed us

174 Recent studies demonstrated that beta(2)-adrenergic receptors (beta(2)ARs) colocalize wit

175 Myocardial overexpression of beta(2)-adrenergic receptors (beta(2)ARs) has been shown

176 zation between prostaglandin E receptors and beta(2)-adrenergic receptors (beta(2)ARs) in airway smoo

177 beta(2)-Adrenergic receptors (beta(2)ARs) regulate cellu

178 Lysosomal degradation of ubiquitinated beta(2)-adrenergic receptors (beta(2)ARs) serves as a ma

179 eptors and diminished relaxation mediated by beta(2)-adrenergic receptors (beta(2)ARs).

180 iated phosphorylation and desensitization of beta(2)-adrenergic receptors (beta(2)ARs).

181 tance regulator (CFTR) chloride channel, the beta-2 adrenergic receptor (beta(2)AR), and fractions of

182 mediated via beta-agonist stimulation of the beta-2-adrenergic receptor (beta 2AR).

183 4, BclII modifying factor, phospholipase C, beta 2, adrenergic receptor, beta 1, actin-binding LIM p

184 EK 293 cells by fluorescence microscopy that beta(2)-adrenergic receptor-beta-arrestin complexes lack

185 Beta(2)-adrenergic receptor (beta2-AR) is a susceptibili

186 A chemical biology approach identifies a beta 2 adrenergic receptor (beta2AR) agonist ARA-211 (Pi

187 To investigate the role of the beta 2 adrenergic receptor (beta2AR) in wound scarring,

188 Three haplotypes found in the beta 2-adrenergic receptor (beta2AR) gene and characteri

189 The beta-2 adrenergic receptor (beta2AR) agonist formoterol

190 pathology, we removed the gene encoding the beta-2 adrenergic receptors (beta2ARs) from a mouse mode

191 The human beta(2)-adrenergic receptor (betaAR) is rapidly desensit

192 This was inhibited by a beta(2)-adrenergic receptor blocker and by an inhibitor

193 ulation that could be rescued by a selective beta(2)-adrenergic receptor blocker and developed sustai

194 dynamics characterization of the GPCR human beta(2) adrenergic receptor bound to the inverse agonist

195 and clathrin-dependent manner like TfnR and beta(2)-adrenergic receptor but requires a distinct gene

196 ay can be used to identify ligand binding to beta(2)-adrenergic receptors, but also the downstream re

197 of the C-terminal cytoplasmic domain of the beta(2)-adrenergic receptor by Akt in vitro identified S

198 413) competes readily for the binding of the beta(2)-adrenergic receptor by gravin, both using in vit

199 the ligand-induced conformational changes in beta(2)-adrenergic receptor by ligands of varied efficac

200 l that gravin binds the receptor through the beta(2)-adrenergic receptor C-terminal cytoplasmic domai

201 ion of the following genes: 5-HT 1c, 5-HTR7, beta 2 adrenergic receptor, c-Fgr, collagen 10 alpha 1,

202 By using a hybrid beta(2)-adrenergic receptor-C-X-C chemokine receptor typ

203 naling pathways in bovine rhodopsin or human beta(2)-adrenergic receptor can be mediated by specific

204 Different conformations of the beta(2) adrenergic receptor cause quenching of the bound

205 nactivation in response to inhibition of the beta(2)-adrenergic receptor causes Galpha(s) to move bac

206 e to stimulation of an exogenously expressed beta(2)-adrenergic receptor causes Galpha(s) to move fro

207 prevented functional resensitization of the beta(2)-adrenergic receptor, converting the temporal pro

208 egulation of membrane proteins including the beta(2)-adrenergic receptor, cystic fibrosis transmembra

209 and the C-terminal cytoplasmic domain of the beta(2)-adrenergic receptor demonstrate that the tyrosin

210 Previous work in the beta(2)-adrenergic receptor demonstrated critical intera

211 ional analysis using x-ray structures of the beta(2)-adrenergic receptor demonstrated that PheVI:09 (

212 on, the C-terminal cytoplasmic domain of the beta(2)-adrenergic receptor demonstrates a potent inhibi

213 In contrast, beta 2-adrenergic receptor desensitization was significa

214 p 2, not observed in either rhodopsin or the beta(2)-adrenergic receptor, directly interacts by means

215 tein kinase A (PKA) signaling pathway by the beta(2) adrenergic receptor (encoded by ADRB2).

216 n Chinese hamster ovary cells, expression of beta(2)-adrenergic receptors enhanced 5-10-fold the acti

217 ary for GRK5-mediated phosphorylation of the beta(2)-adrenergic receptor, even though beta(2)-adrener

218 are involved in translational suppression of beta(2)-adrenergic receptor expression.

219 (S/T)XL, the optimal C-terminal motif in the beta(2)-adrenergic receptor for EBP50/NHERF binding.

220 ate of receptor loss, effectively protecting beta 2-adrenergic receptor from down-regulation even aft

221 l sequence-dependent recycling receptor, the beta-2 adrenergic receptor, from bulk recycling proteins

222 PA/Galpha(13)/p115RhoGEF/RhoA pathway to the beta(2)-adrenergic receptor/Galpha(s)/adenylyl cyclase p

223 lic blood pressure, polymorphisms within the beta(2)-adrenergic receptor gene (Arg16Gly, P=0.009) and

224 tion, and metabolic disorders, including the beta(2)-adrenergic receptor gene ADRB2 and the glucocort

225 The human beta(2)-adrenergic receptor gene has multiple single-nuc

226 hanistic pathways by which variations in the beta(2)-adrenergic receptor gene may influence blood pre

227 Genetic variation in the beta-2 adrenergic receptor gene (ADRB2) has been implica

228 beta(2)-Adrenergic receptor GFP bound to dihydroalprenol

229 equently, the binary complex of agonist with beta(2)-adrenergic receptor GFP.

230 A(2A) adenosine receptor and the beta(1) and beta(2) adrenergic receptors have shown important differ

231 blocks insulin-induced sequestration of the beta(2)-adrenergic receptor, implicating Akt in downstre

232 f internalization and down-regulation of the beta(2)-adrenergic receptor in response to treatment of

233 gonists and insulin provoke sequestration of beta(2)-adrenergic receptors in a synergistic manner.

234 reagent onto the extracellular domain of the Beta-2 adrenergic receptor in HEK293T cells, followed by

235 serve that expression of increased levels of beta(2)-adrenergic receptor increasingly inhibits insuli

236 V(2)R(inh)-02 did not inhibit forskolin or beta(2)-adrenergic receptor-induced cAMP production and

237 ant pathway as they bind to the beta(1)- and beta(2)-adrenergic receptors, initially making contact w

238 ominant-negative K44A dynamin, inhibits both beta(2) adrenergic receptor internalization and bacteria

239 T382A or T382V) states of arrestin-3 promote beta(2)-adrenergic receptor internalization and bind cla

240 s insulin action on cyclic AMP responses and beta(2)-adrenergic receptor internalization.

241 in HEK293 cells and significantly attenuated beta(2)-adrenergic receptor internalization.

242 ed to monitor the incorporation of the human beta(2)-adrenergic receptor into a solid-supported egg p

243 gic receptor and binding of carazolol to the beta(2)-adrenergic receptor involve similar interactions

244 However, when the beta(2) adrenergic receptor is bound to a full agonist,

245 emory consolidation because signaling by the beta(2)-adrenergic receptor is redundant with signaling

246 Its ability to bind and desensitize the beta(2)-adrenergic receptor is, however, unaltered.

247 e QRET and the PathHunter methods a panel of beta(2)-adrenergic receptor ligands (epinephrine, terbut

248 the fusion protein and, in competition with beta(2)-adrenergic receptor ligands, K(d) values for ago

249 oted desensitization of airway smooth muscle beta-2-adrenergic receptors, mediated by G protein-coupl

250 beta(2)-adrenergic receptor mRNA levels and receptor den

251 In the beta(2) adrenergic receptor, mutation of Cys(6.47) to Th

252 esion to laminin, mediated primarily via the beta 2-adrenergic receptor, occurred in SS RBC samples f

253 e recently determined X-ray structure of the beta(2)-adrenergic receptor offers an opportunity to inv

254 ell known and include phosphorylation of the beta(2)-adrenergic receptor on Tyr(350), Tyr(354), and T

255 e neurotransmitter norepinephrine stimulates beta(2)-adrenergic receptors on B lymphocytes to promote

256 ich induces hyperalgesia by direct action at beta(2)-adrenergic receptors on primary afferent nocicep

257 e replaced with analogous sequences from the beta(2)-adrenergic receptor or the m1 muscarinic recepto

258 ligands, such as the carboxyl-termini of the beta(2)-adrenergic receptor or the platelet-derived grow

259 in, engineered A(2A)-adenosine, beta(1)- and beta(2)-adrenergic receptors, permits comparative analys

260 binding to physiological targets, including beta(2)-adrenergic receptor, platelet-derived growth fac

261 Isoproterenol stimulation of the beta(2)-adrenergic receptor promotes dephosphorylation o

262 Interestingly, although beta 2-adrenergic receptor resensitization was potently

263 Blockade of beta(2)-adrenergic receptor sequestration does not alter

264 ngest variant of GIT2 leads to inhibition of beta(2)-adrenergic receptor sequestration, whereas the s

265 peptide inhibitors of dimerization diminish beta(2)-adrenergic receptor signaling [3].

266 Thus, arrestins are selective regulators of beta-2-adrenergic receptor signaling and function in air

267 hat mutants support rapid internalization of beta 2-adrenergic receptor similar to wild type arrestin

268 cyclase, RGS2 inhibited Galpha(s)-Q227L- or beta(2)-adrenergic receptor-stimulated cAMP accumulation

269 beta(2)-adrenergic receptor stimulation by epinephrine c

270 s to enhanced cAMP generation in response to beta(2)-adrenergic receptor stimulation, markedly reduce

271 lar modeling analysis of FFA2 based on human beta(2)-adrenergic receptor structure revealed potential

272 lead-like" molecules were docked against the beta(2)-adrenergic receptor structure.

273 od vessels from mice lacking beta(1)- and/or beta(2)-adrenergic receptor subtypes (beta(1)-KO, beta(2

274 dea that PKA-mediated phosphorylation of the beta(2)-adrenergic receptor switches its predominant cou

275 ize a 1.02 mus all-atom simulation of an apo-beta(2) adrenergic receptor that is missing the third in

276 Herein, we map the regions of the beta(2)-adrenergic receptor that are required for bindin

277 In contrast, cardiac fibroblasts express beta(2)-adrenergic receptors that activate ERK through a

278 lated and unphosphorylated agonist-activated beta 2-adrenergic receptor to manipulate the receptor-ar

279 uestration does not alter the ability of the beta(2)-adrenergic receptor to potentiate insulin action

280 ulin to phosphatidylinositol 3-kinase and to beta(2)-adrenergic receptor trafficking.

281 Reversal of beta(2)-adrenergic receptor translational repression by

282 ecular signaling complexes that comprise the beta(2) adrenergic receptor, trimeric G(s) protein, aden

283 olecular signaling complex consisting of the beta(2) adrenergic receptor, trimeric G(s) protein, and

284 beta(1)- and beta(2)-adrenergic receptors utilize different signaling

285 s is stimulated by sympathetic activation of beta(2)-adrenergic receptors via adrenal catecholamines,

286 The beta(2) adrenergic receptor was found to be directly ass

287 l of the A(2A) AR and was rectified when the beta(2)-adrenergic receptor was used as a template for h

288 or internalization, while the endocytosis of beta(2)-adrenergic receptors was completely prevented.

289 r interactions of fenoterol analogs with the beta(2)-adrenergic receptor, we developed a new agonist

290 tituted cysteine accessibility method in the beta(2)-adrenergic receptor, we have found that in addit

291 e studies of the conformations of the intact beta(2) adrenergic receptor were performed in solution.

292 nes with alpha(1)-, alpha(2)-, beta(1)-, and beta(2)-adrenergic receptors were examined.

293 beta(1)- and beta(2)-Adrenergic receptors were found on both epitheli

294 ty of lysophosphatidic acid to sequester the beta(2)-adrenergic receptor, whereas expression of const

295 carboxyl-terminal cytoplasmic domain of the beta(2)-adrenergic receptor, which engages in PDZ domain

296 r of the PICK1-binding DAT C terminus to the beta(2)-adrenergic receptor, which sorts to recycling up

297 for agonist-promoted internalization of the beta(2)-adrenergic receptor, while arrestin/beta(2)-adap

298 beta(2)-adrenergic receptors with a Y350F mutation faile

299 f sequential ligand binding exhibited by the beta(2)-adrenergic receptor, with the former interaction

300 f two GPCRs: the V2 vasopressin receptor and beta-2 adrenergic receptor, without affecting endocytosi